uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
02 nov. 2021 07h05 HE
|
uniQure Inc.
~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~ ~ Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02,...
Hereditary Disease Foundation Announces 2021 Prizes Recognizing Leadership in Huntington’s Disease Research
27 oct. 2021 13h05 HE
|
Hereditary Disease Foundation
New York, Oct. 27, 2021 (GLOBE NEWSWIRE) -- The Hereditary Disease Foundation today announced the recipients of its 2021 Awards: Elena Cattaneo, Director of the Laboratory of Stem Cell Biology and...
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
09 sept. 2021 08h30 HE
|
Wave Life Sciences USA, Inc.
Only clinical-stage candidate for Huntington’s disease designed to selectively lower mutant HTT and spare wild-type HTT Adaptive trial design to enable faster optimization of dosing and...
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
30 août 2021 07h05 HE
|
uniQure Inc.
~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~ ~ Full Study Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands,...
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
05 août 2021 07h30 HE
|
Wave Life Sciences USA, Inc.
Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study Recruitment ongoing for clinical trials in...
uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
16 juin 2021 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
28 mai 2021 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
13 mai 2021 07h30 HE
|
Wave Life Sciences USA, Inc.
Clinical trials underway with next-generation candidates incorporating PN chemistry Clinical data from PN chemistry programs expected in 2022 In vivo ADAR editing data for AATD program on track for...
Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
10 mai 2021 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021
03 mai 2021 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...